Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study.
Nirosen VijiaratnamChristine GirgesGrace AuldMarisa ChauKate MaclaganAlexa KingSimon S SkeneKashfia ChowdhurySteve HibbertHuw MorrisPatricia LimousinDilan AthaudaCamille B CarrollMichele T HuMonty SilverdaleGordon W DuncanRay ChaudhuriChristine LoSilvia Del DinAlison J YarnallLynn RochesterRachel GibsonJohn DicksonRachael HunterVincenzo LibriThomas FoltyniePublished in: BMJ open (2021)
NCT04232969, ISRCTN14552789.